United States - English - NLM (National Library of Medicine)

dr.reddy's laboratories inc., - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium salt - solution for inhalation - treprostinil as sodium salt 1.74 mg / 2.9 ml - treprostinil - treprostinil - treatment of pulmonary arterial hypertension in patients with nyha class iii symptoms, to increase walk distance.pulmonary hypertension associated with interstitial lung disease (ph-ild; who group 3) to improve exercise ability.

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 1mg - treprostinil (treprostinil sodium) 1mg

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 2.5mg - treprostinil (treprostinil sodium) 2.5mg

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 5mg - treprostinil (treprostinil sodium) 5mg

Canada - English - Health Canada

dr reddy's laboratories ltd - treprostinil (treprostinil sodium) - solution - 10mg - treprostinil (treprostinil sodium) 10mg

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)] . in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations) . in animal studies, no adverse reproductive and developmental

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium - solution for injection - treprostinil as sodium 10 mg/ml - treprostinil - remodulin is indicated as a continuous subcutaneous infusion or intravenous infusion for the treatment of primary pulmonary arterial hypertension and pulmonary arterial hypertension associated with connective tissue disorders. pulmonary hypertension associated with congenital systemic to pulmonary shunts.

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - treprostinil (unii: rum6k67esg) (treprostinil - unii:rum6k67esg) - treprostinil injection is indicated for the treatment of pulmonary arterial hypertension (pah; who group 1) to diminish symptoms associated with exercise. studies establishing effectiveness included patients with nyha functional class ii-iv symptoms and etiologies of idiopathic or heritable pah (58%), pah associated with congenital systemic-to-pulmonary shunts (23%), or pah associated with connective tissue diseases (19%) [see clinical studies (14.1)]. in patients with pah requiring transition from epoprostenol, treprostinil injection is indicated to diminish the rate of clinical deterioration. consider the risks and benefits of each drug prior to transition. none risk summary limited case reports of treprostinil use in pregnant women are insufficient to inform a drug- associated risk of adverse developmental outcomes. however, there are risks to the mother and the fetus associated with pulmonary arterial hypertension (see clinical considerations ). in animal studies, no adverse reproductive and developmen

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium salt - solution for inhalation - treprostinil as sodium salt 1.74 mg / 2.9 ml - treprostinil - treatment of pulmonary arterial hypertension in patients with nyha class iii symptoms, to increase walk distance.pulmonary hypertension associated with interstitial lung disease (ph-ild; who group 3) to improve exercise ability.